How Does Mysimba Work in the Body
Chemical Composition, Mechanism of Action & Metabolic Effects Explained
Key Takeaways: How Mysimba Works
- Dual Action: Combines naltrexone (opioid antagonist) and bupropion (dopamine/norepinephrine reuptake inhibitor)
- Brain Target: Works on hypothalamic POMC neurons to reduce appetite and increase energy expenditure
- Reward System: Reduces food cravings by modulating mesolimbic reward pathways
- Synergy: Naltrexone blocks opioid-mediated autoinhibition, allowing bupropion to stimulate POMC neurons more effectively
- Weight Loss: Clinically proven to help achieve ≥5% weight loss at 16 weeks when combined with diet and exercise
- Duration: Requires gradual dose escalation over 4 weeks; maximum effect by week 16
Mysimba (naltrexone hydrochloride/bupropion hydrochloride) is a prescription weight management medicine that targets specific areas of the brain involved in hunger control and energy balance. By combining two active ingredients, it helps reduce appetite, control cravings, and support sustainable weight loss when used alongside a reduced-calorie diet and increased physical activity.
Important Medical Advice
If you experience suicidal thoughts, seizures, swelling of the face/lips/tongue (angioedema), or signs of a severe allergic reaction, stop taking Mysimba and seek immediate medical attention. Do not take Mysimba with opioids or within 14 days of stopping MAO inhibitors. Always inform your doctor about any mental health changes.
Mysimba Chemical Composition & Molecular Structure
Mysimba contains two distinct active substances in a fixed-dose combination: naltrexone hydrochloride (8 mg) and bupropion hydrochloride (90 mg) per prolonged-release tablet.
Active Ingredients: Structural Details
(5α)-17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-one hydrochloride
An opioid receptor antagonist derived from oxymorphone. It blocks μ- and κ-opioid receptors without producing agonist effects.
Molecular Formula: C20H23NO4·HCl
Molecular Weight: 377.86 g/mol
(±)-2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one hydrochloride
A norepinephrine-dopamine reuptake inhibitor (NDRI) chemically unrelated to other antidepressants.
Molecular Formula: C13H18ClNO·HCl
Molecular Weight: 276.20 g/mol
Key Pharmaceutical Properties
| Property | Naltrexone | Bupropion | Clinical Relevance |
|---|---|---|---|
| Solubility | Freely soluble in water | Freely soluble in water | Allows rapid dissolution and absorption |
| Protein Binding | 21% | 84% | Bupropion's high binding affects drug interactions |
| Bioavailability | 5–40% (extensive first-pass) | 5–20% (extensive first-pass) | Prolonged-release formulation optimises exposure |
| Metabolism | Primarily dihydrodiol dehydrogenase | CYP2B6 (major), CYP1A2, CYP2C19 | Genetic variations can affect response and side effects |
🗒️ Pharmaceutical Insight: The prolonged-release formulation delays absorption to maintain therapeutic levels over 24 hours, reducing peak-related side effects. Each tablet contains 8 mg naltrexone HCl (equivalent to 7.2 mg naltrexone base) and 90 mg bupropion HCl (equivalent to 78 mg bupropion base).
Mysimba Mechanism of Action: How Naltrexone and Bupropion Work Together
Mysimba's weight-lowering effect results from synergistic actions on two distinct neuronal pathways in the hypothalamus, the brain's appetite control centre.
The Hypothalamic Pathway (POMC Neurons)
- Pro-opiomelanocortin (POMC) neurons in the arcuate nucleus produce α-melanocyte-stimulating hormone (α-MSH), which reduces appetite.
- Normally, POMC neurons are inhibited by opioidergic inputs (β-endorphin) that act on μ-opioid receptors.
- Naltrexone blocks these μ-opioid receptors, removing the natural brake on POMC neurons.
- Bupropion stimulates POMC neurons by increasing dopamine and norepinephrine levels in the synapse, enhancing their firing rate.
- Combined effect: POMC activity is robustly increased → more α-MSH released → appetite suppression and increased energy expenditure.
Mesolimbic Reward System
| Component | Normal Role | Mysimba Effect |
|---|---|---|
| Dopamine pathways (nucleus accumbens) | Mediate pleasure and reward from food | Bupropion inhibits dopamine reuptake, reducing the reward-driven urge to overeat |
| Opioid receptors (ventral tegmental area) | Enhance hedonic response to palatable foods | Naltrexone blocks opioid receptors, dampening food cravings and binge-eating tendencies |
🗒️ Physiological Insight: Mysimba does not suppress appetite by a single mechanism—it both reduces hunger signals and decreases the rewarding properties of food, making it easier to adhere to a reduced-calorie diet.
Effects on Brain Reward System and Food Cravings
Food intake is not only driven by hunger but also by pleasure. Mysimba targets the brain's reward circuitry to reduce the desire for high-calorie, palatable foods.
How Cravings Are Reduced
- Naltrexone attenuates the release of dopamine in response to food cues by blocking opioid receptors on GABAergic interneurons in the ventral tegmental area.
- Bupropion elevates tonic dopamine levels, which may reduce phasic dopamine spikes triggered by food stimuli, leading to diminished craving intensity.
- Together, they shift the reward balance, making healthy food choices more sustainable.
Clinical Evidence in Craving Reduction
Studies have shown that patients taking Mysimba report significantly fewer food cravings, particularly for sweets and fatty foods, compared to placebo. This effect is most pronounced in the first 12 weeks of treatment.
🗒️ Neuropsychiatric Insight: Because Mysimba influences dopamine pathways, patients with a history of bipolar disorder or seizure disorders require careful evaluation before treatment (see emergency note).
Mysimba Metabolic Effects and Duration in the Body
Beyond appetite suppression, Mysimba exerts metabolic effects that contribute to weight loss and improved metabolic health.
Metabolic Actions
- Energy expenditure: Animal studies suggest increased thermogenesis via sympathetic activation.
- Insulin sensitivity: Weight loss itself improves insulin resistance; however, bupropion may have direct beneficial effects on glucose metabolism.
- Lipid profile: Clinical trials show improvements in triglycerides and HDL cholesterol associated with weight reduction.
Duration of Action and Half-Life
Naltrexone
Half-life: ~5 hours
Active metabolite: 6β-naltrexol (half-life ~13 hours)
Time to steady state: 2–3 days
Bupropion
Half-life: ~21 hours
Active metabolites: Hydroxybupropion (half-life ~20 hours), threohydrobupropion, erythrohydrobupropion
Time to steady state: 5–8 days
🗒️ Pharmacokinetic Insight: The long half-life of bupropion and its metabolites allows once-daily dosing after dose stabilisation. However, it also means that if side effects occur, they may take several days to resolve after stopping treatment.
Absorption, Distribution & Elimination of Mysimba
Understanding how Mysimba moves through the body helps explain its dosing schedule and drug interactions.
Pharmacokinetic Profile
Absorption
Tmax (fed): 3 hours (both components)
Food effect: High-fat meal increases Cmax by 30–50% (take with food to minimise nausea)
Bioavailability: Low due to first-pass metabolism
Distribution
Volume (Vd): Naltrexone: 1350 L; Bupropion: 2000 L
Crosses blood-brain barrier: Yes (both)
Placental passage: Yes (contraindicated in pregnancy)
Elimination
Renal: Naltrexone and metabolites (53–79% in urine)
Hepatic: Bupropion extensively metabolised (CYP2B6)
Half-life elimination: See metabolic section
Special Population Considerations
| Population | Effect on Mysimba | Dosing Consideration |
|---|---|---|
| Hepatic impairment (mild-moderate) | Increased exposure (up to 3-fold) | Contraindicated in severe hepatic impairment; use with caution in mild-moderate |
| Renal impairment (end-stage) | Accumulation of metabolites | Contraindicated in end-stage kidney disease |
| Elderly (≥65 years) | Limited data, may be more sensitive | Use caution; not recommended over 75 years |
| CYP2B6 poor metabolisers | Higher bupropion levels | Increased risk of seizures and side effects |
Clinical Efficacy for Weight Management
Mysimba is indicated for adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidaemia).
Pivotal Clinical Trial Results (COR studies)
| Trial | Population | Weight Loss at 56 weeks (Mysimba vs placebo) |
|---|---|---|
| COR-I | General obese/overweight | 6.1% vs 1.3% (placebo-subtracted: 4.8%) |
| COR-II | General obese/overweight | 6.4% vs 1.2% (placebo-subtracted: 5.2%) |
| COR-BMOD | With intensive behavioural modification | 9.3% vs 5.1% (placebo-subtracted: 4.2%) |
| COR-Diabetes | Type 2 diabetes patients | 5.0% vs 1.8% (placebo-subtracted: 3.2%) |
Predictors of Response
Your doctor will assess response at 16 weeks. If you have not lost at least 5% of your initial body weight, treatment discontinuation should be considered, as continued therapy is unlikely to be effective.
- Week 1-4: Gradual dose escalation to minimise side effects (see dosing schedule).
- Week 16: Primary efficacy assessment – ≥5% weight loss indicates good response.
- Annual review: Long-term benefit-risk reassessment.
🗒️ Prescribing Insight: Mysimba is not a standalone magic pill—it works best when combined with structured dietary advice and physical activity. The medication helps you adhere to lifestyle changes by reducing hunger and cravings.
Mysimba Mechanism FAQs
How does Mysimba suppress appetite?
Mysimba increases the activity of POMC neurons in the hypothalamus, which produce α-MSH—a molecule that signals satiety. Naltrexone blocks opioid inhibition of these neurons, and bupropion directly stimulates them.
How long does Mysimba stay in your system?
Bupropion has a half-life of about 21 hours, so it takes roughly 5 days to be eliminated after the last dose. Naltrexone is faster (5 hours), but its active metabolite 6β-naltrexol lasts longer (13 hours).
Does Mysimba affect metabolism or just appetite?
Yes, Mysimba may slightly increase energy expenditure through sympathetic activation, but its primary effect is appetite suppression. The majority of weight loss comes from reduced calorie intake.
Can Mysimba cause weight loss without diet and exercise?
Mysimba is approved only as an adjunct to a reduced-calorie diet and increased physical activity. It enhances adherence to lifestyle changes but is not effective on its own.
Is Mysimba addictive?
Bupropion has a very low potential for abuse, and naltrexone blocks opioid receptors, so it does not cause dependence. However, do not stop suddenly without medical advice.
Need Support for Weight Management?
If you're struggling with obesity or overweight and want to understand if Mysimba could be right for you, speak with a UK-registered doctor through a confidential online consultation.
Secure Prescription & Next-Day Delivery
MHRA-compliant | GPhC-registered pharmacy | Discreet packaging | UK-registered doctors
Start Weight Loss ConsultationRelated Mysimba Guides
Medical Content Manager
Nabeel is a co-founder and medical content manager of Chemist Doctor. He works closely with our medical team to ensure the information is accurate and up-to-date.
Medical Doctor
Dr. Feroz is a GMC-registered doctor and a medical reviewer at Chemist Doctor. He oversees acute condition and urgent care guidance.
Medical Director
Usman is a co-founder and medical director of Chemist Doctor. He leads the organisation's strategic vision, bridging clinical and operational priorities.
Review Date: 22 February 2026
Next Review: 22 August 2026
Published on: 22 February 2026
Last Updated: 22 February 2026